Candel Therapeutics (CADL) Corporate Presentation summary

Clinical pipeline and product highlights

• CAN-2409 is an off-the-shelf viral immunotherapy with positive phase 3 results in prostate cancer, and phase 2a data in pancreatic and NSCLC, showing improved survival and strong safety profile.

• CAN-3110 is an oncolytic HSV-1 virus with proof of concept in recurrent high-grade glioma, demonstrating encouraging survival and immune activation, with Fast Track and Orphan Drug designations.

• Both products are protected by long-term IP and data exclusivity, with low-cost manufacturing and precommercialization activities underway for CAN-2409.

• Cash position of $87M as of September 2025, with a term loan facility of up to $130M, providing runway into Q1 2027.

• Experienced leadership and a renowned scientific advisory board support ongoing development and commercialization.

CAN-2409 in prostate cancer: clinical and commercial outlook

• Phase 3 trial in intermediate/high-risk localized prostate cancer (n=745) met primary endpoint, showing a 30% risk reduction in disease recurrence (HR=0.70, p=0.0155) and 38% reduction in prostate cancer-specific recurrence (HR=0.62, p=0.0046).

• Significant improvements in PSA nadir rates and pathological complete response at 2 years (80.4% vs 63.6% for placebo, p=0.0015).

• Well-tolerated with lower rates of serious adverse events and treatment discontinuation compared to placebo.

• Addressable US market estimated at $10–16B, with strong payor support for reimbursement and pricing in line with other prostate cancer therapies.

• BLA submission expected in Q4 2026, with comprehensive commercial launch planning and stakeholder engagement underway.

CAN-2409 in pancreatic and lung cancer: clinical data

• In borderline resectable pancreatic cancer, phase 2a trial showed median OS of 31.4 months for CAN-2409 vs 12.5 months for control, with 71.4% 24-month survival rate and favorable safety.

• In NSCLC patients with inadequate response to ICI, phase 2a trial showed mOS of 24.5 months (all), 21.5 months (progressive disease), and 25.4 months (nonsquamous), all exceeding historical controls.

• Systemic antitumor activity observed, including abscopal effects and long-term survival in a significant subset of patients.

• Safety profile in both indications was favorable, with most adverse events mild to moderate.